May 21 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Moderna's decision to withdraw ...

Previously, the COVID-19 immunizations made by Pfizer and Moderna were the only mRNA vaccines on the market.

We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...

CLAIM: A COVID-19 test patent application is dated 2020 but was actually filed in 2015. THE FACTS: The patent application, for a system to determine if someone has a viral infection such as COVID-19, ...

FORT WAYNE, Ind.--(BUSINESS WIRE)--Enterprise Health, an occupational and employee health IT solution provider, today launched Channel 19, a stand-alone application to help employers and hospital ...

Rand Paul reveals documents showing CBP intercepted undeclared biological materials tied to a U.S.-China coronavirus research network as early as 2018.

Moderna Inc. said it has “voluntarily” withdrawn its application for regulatory approval for its combination Covid and flu shot for people 50 and over, a setback for the company. The biotech company ...